Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit (2024)

1. Sartor O, Bono JD, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091–103.

   Article CAS PubMed PubMed Central Google Scholar

2. Sartor O, Castellano Gauna DE, Herrmann K, de Bono JS, Shore ND, Chi KNN et al. LBA13 - Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Annals of Oncology. 2023;34:S1254–335.

3. Olivier T, Powell K, Prasad V. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4–6.

   Article CAS PubMed Google Scholar

4. Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer. 2019;106:196–211.

   Article PubMed Google Scholar

5. Paggio JCD, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, et al. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncol. 2021;7:728–34.

   Article PubMed Google Scholar

6. Walia A, Haslam A, Prasad V. FDA Validation of Surrogate Endpoints in Oncology: 2005-2022. J Cancer Policy. 2022;34:100364.

   Article PubMed Google Scholar

7. Walia A, Tuia J, Prasad V. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nat Rev Clin Oncol. 2023;20:885–95.

   Article PubMed Google Scholar

8. Gharzai LA, Jiang R, Jaworski EM, Rivera KM, Dess RT, Jackson WC, et al. Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer. NEJM Evid. 2023;2:10. https://doi.org/10.1056/EVIDoa2200195.

   Article Google Scholar

9. Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99–107.

   See Also

   Bibliografía Histórica del Ecuador - PDFCOFFEE.COM[PDF] CAYMAN ISLANDS GAZETTE - Free Download PDFGemeenschappelijk Hof van Justitie van Aruba, Curaçao, Sint Maarten en van Bonaire, Sint Eustatius en Saba, 18-06-2024, ECLI:NL:OGHACMB:2024:89, CUR2022H00267ECLI:NL:OGHACMB:2024:89 - PONT Zorg&Sociaal

   Article CAS PubMed Google Scholar

10. Samuel JN, Booth CM, Eisenhauer E, Brundage M, Berry SR, Gyawali B. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. JAMA Oncol. 2022;8:879–86.

    Article PubMed PubMed Central Google Scholar

11. Hilal T, Sonbol MB, Prasad V. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA Oncol. 2019;5:887–6.

    Article PubMed PubMed Central Google Scholar

12. Olivier T, Haslam A, Prasad V. Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials. JAMA Netw Open. 2022;5:e2144770.

    Article PubMed PubMed Central Google Scholar

13. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24:1802–7.

    Article CAS PubMed Google Scholar

14. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, et al. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017;72:10–3.

    Article CAS PubMed Google Scholar

15. Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730–9.

    Article CAS PubMed Google Scholar

16. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl J Med. 2020;382:2091–102.

    Article PubMed Google Scholar

17. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N. Engl J Med. 2020;383:2345–57.

    Article CAS PubMed Google Scholar

18. Kwon DH, Booth CM, Prasad V. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? Eur Urol. 2021;79:710–12.

    Article CAS PubMed Google Scholar

    See Also

    How Australian healthcare leaders want to transform their workforce - Health Recruitment Australia

19. Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119–34.

    Article CAS PubMed Google Scholar

20. Wambeke SV, Vera-Badillo FE, Gyawali B. Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care? J Clin Oncol. 2022;40:1518–21.

    Article PubMed Google Scholar

21. Haslam A, Prasad V. When is crossover desirable in cancer drug trials and when is it problematic? Ann Oncol. 2018;29:1079–81.

    Article CAS PubMed PubMed Central Google Scholar

22. Gyawali B. Problematic crossovers in cancer drug trials. Nat Rev Clin Oncol. 2023;20:815–6.

    Article PubMed Google Scholar

23. Morris MJ, Sartor O, de Bono JS, Fizazi K, Tagawa ST. Reply to Timothee Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:7–8. https://doi.org/10.1016/j.eururo.2022.08.022.

    Article CAS PubMed Google Scholar

24. Ardolino LC, Dear R, Armstrong AJ, Gillessen S, Joshua AM. Re: Timothee Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4–6.

    Article Google Scholar

25. Wit RD, Bono JD, Sternberg CN, Fizazi K, Tombal B, Wülfing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019;381:2506–18.

    Article PubMed Google Scholar

26. Rosen K, Prasad V, Chen EY. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. Eur J Cancer. 2020;141:152–61.

    Article CAS PubMed Google Scholar

27. Olivier T, Prasad V. Equal censoring but still informative: When the reasons for censoring differ between treatment arms. Eur J Cancer. 2024;201:113942.

    Article PubMed Google Scholar

28. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N. Engl J Med. 2012;366:520–9.

    Article CAS PubMed Google Scholar

29. Prasad V, Bilal U. The role of censoring on progression free survival: Oncologist discretion advised. Eur J Cancer. 2015;51:2269–71.

    Article PubMed Google Scholar

30. Fojo T, Simon RM. Inappropriate censoring in Kaplan-Meier analyses. Lancet Oncol. 2021;22:1358–60.

    Article PubMed Google Scholar

31. Tannock IF, Pond GR, Booth CM. Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead. JAMA Oncol. 2022;8:679–80.

    Article PubMed Google Scholar

32. Gilboa S, Pras Y, Mataraso A, Bomze D, Markel G, Meirson T. Informative censoring of surrogate end-point data in phase 3 oncology trials. Eur J Cancer. 2021;153:190–202.

    Article PubMed Google Scholar

33. Schnog J-JB, Samson MJ, Gans ROB, Duits AJ. An urgent call to raise the bar in oncology. Br J Cancer. 2021;125:1477–85.

    Article PubMed PubMed Central Google Scholar

34. Gyawali B, Booth CM. Cancer treatments should benefit patients: a common-sense revolution in oncology. Nat Med. 2022;28:617–20.

    Article CAS PubMed Google Scholar

35. Schnog J-JB, Samson MJ, Duits AJ. Contemporary oncology trials, drug approvals and the physician-patient relationship. Lancet Regional Health Am. 2022;11:100247. https://doi.org/10.1016/j.lana.2022.100247.

    Article Google Scholar

36. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, et al. Trends in drug revenue among major pharmaceutical companies: A 2010‐2019 cohort study. Cancer. 2022;128:311–6.

    Article PubMed Google Scholar

Download references